HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Target
10/15/2026
Impact: 75
Healthcare
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Krystal Biotech (NASDAQ: KRYS) and maintained a price target of $361 for the stock.
AI summary, not financial advice
Share: